Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYXATA vs CHOLESTYRAMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
Pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise capacity and delay clinical worsening,Treatment of PAH in combination with other PAH therapies
Primary hypercholesterolemia (Type IIa hyperlipoproteinemia),Pruritus associated with partial biliary obstruction and primary biliary cirrhosis,Pseudomembranous colitis (Clostridioides difficile infection)-associated diarrhea (adjunctive),Diarrhea associated with bile acid malabsorption,Eczema (off-label),Hyperoxaluria (off-label)
KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
Terminal elimination half-life is 12–15 hours in adults with normal renal function; extends to 22–30 hours in moderate renal impairment (Cr Cl 30–50 m L/min) and up to 48 hours in severe impairment (Cr Cl <30 m L/min).
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Primarily hepatic via CYP3A4 and CYP2C19; minor contribution from UGT1A1, UGT1A3, UGT1A9. Active metabolite (M14) via dealkylation.
Cholestyramine is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Renal excretion accounts for approximately 70% of elimination (60% unchanged, 10% as metabolites); biliary/fecal excretion accounts for 25% (primarily as metabolites); minor metabolic clearance (5%) via CYP3A4.
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
88–92% bound to albumin and alpha-1-acid glycoprotein.
Not applicable; cholestyramine is not absorbed and does not bind to plasma proteins.
0.8–1.2 L/kg, indicating extensive extravascular distribution into tissues including brain and myocardium.
Not applicable; due to lack of systemic absorption, Vd is essentially zero.
Oral: 35–45% (due to first-pass metabolism); IM: 80–90%; IV: 100%.
Oral: <0.1% (negligible systemic absorption); cholestyramine acts locally in the gastrointestinal tract.
No dosage adjustment is required for renal impairment. Landiolol is minimally renally excreted (approximately 1% unchanged). However, use caution in patients with severe renal impairment (Cr Cl < 30 m L/min) due to limited data.
No dosage adjustment required for renal impairment; caution in patients with severe renal disease due to risk of hyperchloremic metabolic acidosis
For mild hepatic impairment (Child-Pugh Class A): No dosage adjustment needed. For moderate to severe hepatic impairment (Child-Pugh Class B or C): Reduce initial infusion rate to 0.05 mg/kg/min and titrate cautiously; maximum infusion rate of 0.2 mg/kg/min is recommended due to reduced clearance.
Use with caution in cirrhosis or cholestatic disorders; no specific Child-Pugh guidelines; monitor for increased bleeding risk due to vitamin K malabsorption
Weight-based dosing: Loading dose of 0.125 mg/kg intravenously over 1 minute, followed by continuous infusion starting at 0.05 mg/kg/min, titrated to effect. Maximum infusion rate is 0.3 mg/kg/min. Safety and efficacy established in pediatric patients aged 1 to <18 years.
Initial 240 mg/kg/day (approximately 0.625 g/kg/day) divided into 2-3 doses, titrated based on response; maximum 8 g/day
Elderly patients (≥65 years): Start at the lower end of the dosing range (initial infusion rate of 0.05 mg/kg/min) and titrate slowly due to potential decreased hepatic function and increased sensitivity. No specific dose adjustment mandated, but monitor heart rate and blood pressure closely.
Start at low end of dosing range (4 g/day) due to increased risk of constipation and fecal impaction; monitor for electrolyte disturbances and drug interactions
Embryofetal toxicity: Must be avoided in pregnancy; females of reproductive potential must use reliable contraception and have monthly pregnancy tests.
No FDA black box warning.
Hepatotoxicity (requires monthly liver function monitoring); fluid retention (peripheral edema, may require diuretics); hematologic changes (hemoglobin decrease, requires periodic monitoring); pulmonary veno-occlusive disease (PVOD) should be excluded.
May reduce absorption of fat-soluble vitamins (A, D, E, K) and folic acid; supplementation may be required.,May impair absorption of other medications (e.g., digoxin, warfarin, thyroid hormones); administer at least 4-6 hours before or after cholestyramine.,May cause hyperchloremic metabolic acidosis, especially in pediatric patients.,May exacerbate hemorrhoids due to constipation.,Use with caution in patients with phenylketonuria (contains aspartame in some formulations).
Pregnancy (absolute); hypersensitivity to macitentan or any component; concomitant use with strong CYP3A4 inducers (e.g., rifampin) (relative); severe hepatic impairment (Child-Pugh C) (relative).
Complete biliary obstruction (unable to excrete bile into intestine),Hypersensitivity to cholestyramine or any component,Phenylketonuria (if product contains aspartame)
Avoid alcohol and grapefruit juice. High-fat meals may delay absorption; take on empty stomach for consistent effect.
Cholestyramine may interfere with absorption of fat-soluble vitamins (A, D, E, K). Long-term use may require supplementation. Administer with meals to bind bile acids. High-fiber foods may help counteract constipation. Avoid taking cholestyramine close to other medications or foods that require optimal absorption.
No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.
Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. However, due to potential maternal fat-soluble vitamin deficiency (A, D, E, K) caused by the drug, indirect fetal risk exists, especially in the first trimester for neural tube defects (vitamin A) and second/third trimester for coagulation (vitamin K). Use only if clearly needed and monitor maternal vitamin levels.
No human data; M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise against breastfeeding during therapy.
Cholestyramine is not excreted into breast milk due to negligible systemic absorption. It is considered compatible with breastfeeding, as no adverse effects on the nursing infant have been reported. M/P ratio is not applicable. Monitor infant for signs of vitamin deficiency if mother uses high doses long-term.
No pharmacokinetic data in pregnancy; no dose adjustment guidelines available. Use with caution and therapeutic drug monitoring if applicable.
No dose adjustment is needed for pregnancy because cholestyramine is not absorbed systemically. However, consider increasing the dose if concurrent vitamin supplementation is used, as cholestyramine may bind and reduce absorption of fat-soluble vitamins. Administer vitamins at least 1 hour before or 4-6 hours after cholestyramine. Monitor for adequate therapeutic effect; dose may be adjusted based on clinical response (e.g., pruritus or diarrhea control).
KYXATA (potassium oxyrate) is a CNS depressant; avoid concurrent use with alcohol or other sedatives. Monitor for respiratory depression, especially in elderly or COPD patients. Taper dose to prevent withdrawal seizures. Not a controlled substance but carries abuse potential.
Cholestyramine is a bile acid sequestrant used to lower LDL cholesterol by binding bile acids in the intestine, increasing their fecal excretion, and upregulating hepatic LDL receptors. It is also used for pruritus associated with cholestasis and for diarrhea due to bile acid malabsorption. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine, as it can impair absorption of many drugs (e.g., warfarin, digoxin, thyroid hormones). Monitor for constipation, which is common and can be severe; increase fiber and fluid intake. Cholestyramine can cause hypertriglyceridemia; check triglycerides before and during therapy. It may reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation with long-term use.
Take exactly as prescribed; do not increase dose or frequency.,Avoid driving or operating machinery until you know how KYXATA affects you.,Do not drink alcohol while taking this medication.,Do not stop suddenly; abrupt discontinuation may cause seizures.,Report any unusual changes in mood, thoughts, or behavior.,Store at room temperature, away from moisture and heat.
Take this medication exactly as prescribed, usually 2-4 times daily with meals or at bedtime.,Mix the powder with at least 4-8 ounces of water, fruit juice, or non-carbonated beverage; stir well and drink immediately. Do not swallow dry powder.,Do not take other medications or supplements within 1 hour before or 4-6 hours after taking cholestyramine, as it can prevent their absorption.,Increase fluid and dietary fiber intake to help prevent constipation. Notify your doctor if constipation becomes severe or if you have stomach pain.,Inform your doctor if you develop unusual bleeding or bruising, which may indicate vitamin K deficiency.,Cholestyramine may increase blood triglyceride levels; your doctor will monitor your blood lipid profile.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYXATA vs CHOLESTYRAMINE, answered by our medical review team.
KYXATA is a Unknown that works by Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).. CHOLESTYRAMINE is a Bile Acid Sequestrant that works by Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYXATA and CHOLESTYRAMINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYXATA is: KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.. The standard adult dose of CHOLESTYRAMINE is: 4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYXATA and CHOLESTYRAMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYXATA is classified as Category C. No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.. CHOLESTYRAMINE is classified as Category C. Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. Howe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.